Edaravone Drug Asset Due Diligence Report 2026

This Edaravone Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

108

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Edaravone can convert its Small molecule drug profile and Free radicals biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Edaravone (query alias: edaravone)
Modality / target	Small molecule drug; Free radicals; Free radicals inhibitors, Neuroprotectants
Highest global status	Approved
Originator	Tanabe Pharma Corp.
Active developers	Beijing Tiantan Hospital, Shanghai Auzone Biological Technology Co., Ltd., Treeway BV

The MCP disease footprint includes Amyotrophic Lateral Sclerosis, Brain Infarction, Acute Ischemic Stroke. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
ChiCTR2600117649	Phase 4	Not yet recruiting	37	Postoperative pulmonary complications
ChiCTR2600125711	Phase 2	Not yet recruiting	53	Proportion of patients achieving a >=25% reduction in brain edema volume on FLAIR-MRI at 3 months after treatment
ChiCTR2600119095	Not Applicable	Pending	79	Change in MoCA score from baseline at 6 months

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Exploratory Post Hoc Analysis of Neutrophil-to-Lymphocyte Ratio as a Novel Response Biomarker for Edaravone Oral Suspension-Treated Patients With ALS

Phase 3; n=442; evaluation: Positive. Reported fields: NLR(48 weeks): P-Value = 0.065; P-Value = 0.038; NLR(48 weeks): P-Value = 0.065; P-Value = 0.038; NLR(48 weeks): P-Value = 0.065; P-Value = 0.038

Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis

Phase 3; n=243; evaluation: Positive. Reported fields: ALSFRS-R = 35.1 point

Analysis of Long‐Term Function and Survival of Edaravone Oral Suspension–Treated Patients With Amyotrophic Lateral Sclerosis Using <scp>PRO</scp>‐<scp>ACT</scp> Data as Historical Placebo Controls

Not Applicable; n=420; evaluation: Positive. Reported fields: survival benefit = 78 edaravone oral suspension-treated patients from Studies MT-1186-A02/A04 demonstrated a survival benefit versus 78 matched PRO-ACT placebo patients (p = 0.005) ; survival benefit = 78 edaravone oral suspension-treated patients from Studies MT-1186-A02/A04 demonstrated a survival benefit versus 78 matched PRO-ACT placebo patients (p = 0.005)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Edaravone addresses Amyotrophic Lateral Sclerosis, Brain Infarction, Acute Ischemic Stroke. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 6 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-12-22	Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)	Approved	US$2,500.0M stated total
2024-07-12	华东医药股份有限公司关于全资子公司与澳宗生物签署产品独家许可协议的公告	Phase 3	US$13.8M upfront; US$163.2M milestones
2023-08-27	Specialised Therapeutics acquires commercialisation rights to new oral MND therapy	Phase 3	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Edaravone oral instant film as well as preparation method and application thereof”. The milestone feed surfaced a patent-application signal described as “Solid oral quick-release preparation containing edaravone and dextroborneol”. The milestone feed surfaced a patent-application signal described as ““an improved process for the preparation of edaravone of formula (x)””.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO